XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 123 filers reported holding XENON PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $611,000 | -21.8% | 20,000 | -20.0% | 0.13% | -3.0% |
Q4 2021 | $781,000 | -61.9% | 25,000 | -77.3% | 0.13% | +73.7% |
Q2 2021 | $2,048,000 | +63.4% | 110,000 | +57.1% | 0.08% | +61.7% |
Q1 2021 | $1,253,000 | -41.5% | 70,000 | -49.8% | 0.05% | -57.3% |
Q4 2020 | $2,143,000 | +36.7% | 139,360 | -1.6% | 0.11% | +29.4% |
Q3 2020 | $1,568,000 | -11.7% | 141,660 | 0.0% | 0.08% | -5.6% |
Q2 2020 | $1,776,000 | +10.6% | 141,660 | 0.0% | 0.09% | -90.1% |
Q1 2020 | $1,606,000 | -55.1% | 141,660 | -48.0% | 0.91% | +62.5% |
Q4 2019 | $3,573,000 | +33.8% | 272,543 | -8.1% | 0.56% | +33.5% |
Q3 2019 | $2,671,000 | -10.7% | 296,500 | -2.2% | 0.42% | +106.9% |
Q2 2019 | $2,991,000 | -3.0% | 303,300 | 0.0% | 0.20% | -32.2% |
Q1 2019 | $3,082,000 | +92.9% | 303,300 | +19.7% | 0.30% | -7.7% |
Q4 2018 | $1,598,000 | -73.9% | 253,300 | -45.4% | 0.32% | -20.6% |
Q3 2018 | $6,129,000 | +38.2% | 464,300 | -3.7% | 0.41% | +2.5% |
Q2 2018 | $4,436,000 | – | 482,200 | – | 0.40% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |